Background
VIALE-A was a phase III randomized double-blind placebo-controlled trial evaluating venetoclax (BCL-2 inhibitor) plus azacitidine versus placebo plus azacitidine in newly diagnosed AML in patients ineligible for intensive induction due to age ≥75 or comorbidities. Prior phase Ib data had shown striking response rates with venetoclax-azacitidine; VIALE-A was designed to confirm these findings randomly and establish the combination as a standard of care for unfit patients, a large underserved AML population.
Interventions and follow up
Arm A: Azacitidine 75 mg/m² SC/IV days 1–7 q28d + placebo days 1–28 until progression (n=145)
Arm B: Azacitidine 75 mg/m² SC/IV days 1–7 q28d + venetoclax (3-day ramp-up to 400 mg PO daily) until progression (n=286)
Primary endpoint: Overall survival; key secondary: CR, composite CR (CR+CRi), event-free survival, safety
mFollow up: 20.5 months
Arm B: Azacitidine 75 mg/m² SC/IV days 1–7 q28d + venetoclax (3-day ramp-up to 400 mg PO daily) until progression (n=286)
Primary endpoint: Overall survival; key secondary: CR, composite CR (CR+CRi), event-free survival, safety
mFollow up: 20.5 months
Results
mOS: 14.7 vs 9.6 months (ven+aza vs aza), HR 0.66, 95% CI 0.52–0.85, P<.001
CR: 36.7% vs 17.9%
Composite CR (CR+CRi): 66.4% vs 28.3% (P<.001)
mDuration of remission: 17.5 vs 13.4 months
MRD negativity among responders: 23.4% vs 7.6%
CR: 36.7% vs 17.9%
Composite CR (CR+CRi): 66.4% vs 28.3% (P<.001)
mDuration of remission: 17.5 vs 13.4 months
MRD negativity among responders: 23.4% vs 7.6%
Adverse events
Hematologic (Grade ≥3, ven+aza vs aza): neutropenia 42% vs 29%, thrombocytopenia 45% vs 38%, febrile neutropenia 42% vs 19%
Infections: serious infections 40% vs 26%; pneumonia common
Other: tumor lysis syndrome 1%; 30-day mortality 7.2% vs 9.4% (not significantly different); QTc prolongation rare
Infections: serious infections 40% vs 26%; pneumonia common
Other: tumor lysis syndrome 1%; 30-day mortality 7.2% vs 9.4% (not significantly different); QTc prolongation rare
Conclusions
Venetoclax plus azacitidine significantly improved OS (14.7 vs 9.6 months, HR 0.66) and achieved dramatically higher composite remission rates (66% vs 28%) versus azacitidine alone in AML unfit for intensive chemotherapy, establishing ven+aza as the standard of care for this population and the first major OS improvement in this setting in over a decade.
Key Limitations
Older population (median age 76) limits generalizability to younger unfit patients; cytopenia management complex with frequent dose interruptions; venetoclax administered 28 days per cycle, whereas 14-day durations are commonly used in practice with post-trial data suggesting reduced myelosuppression at similar efficacy; reduced benefit in TP53-mutated and complex-cytogenetics subsets; venetoclax requires azole antifungal CYP3A4 dose adjustment; 2:1 randomization yields a smaller control arm limiting some subgroup analyses.
Clinical Context
VIALE-A led to full FDA approval of venetoclax + azacitidine for AML in adults ≥75 or unfit for intensive induction in October 2020 and is endorsed in ELN 2022 recommendations for unfit patients. It fundamentally changed the treatment landscape for older/unfit AML, making ven+aza the standard of care. The combination is active across IDH1/2-mutated, NPM1-mutated, and spliceosome-mutated AML, with reduced efficacy in TP53-mutated and complex-cytogenetics disease. VIALE-C confirmed ven + low-dose cytarabine activity; AGILE established ivosidenib + azacitidine for IDH1-mutant AML. Triplet integration of ven+aza with targeted agents is an active area of investigation.